Login to Your Account



Endocyte Ovarian Cancer Duo Is Nearing European Market

By Catherine Shaffer


Wednesday, April 27, 2011
Endocyte Inc.'s stock jumped 25 percent Tuesday on news that it would be applying for marketing authorization from the European Medicines Agency for two of its products: ovarian cancer candidate EC145 and a companion imaging diagnostic EC20 for patient selection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription